New OA Cell Therapy On Horizon As JointStem Study Succeeds
A novel stem cell therapy for osteoarthritis developed by South Korean biotech Nature Cell is set to debut in the country this year, providing an alternative for advanced patients who have limited treatment options.
You may also be interested in...
The Korean biotech’s CEO and several other executives’ alleged involvement in stock price manipulation using false and exaggerated information on a pipeline stem cell therapy has damaged the credibility of its R&D efforts and shocked the domestic industry, although their fate remains to be determined after court trials.
In a rare large gene therapy deal, South Korea’s Kolon is making inroads into the Japanese market through Invossa, its genetically modified allogeneic cell therapy for osteoarthritis. The agreement with Mitsubishi Tanabe could pave the way for more global licensing agreements in a growing segment.
In another positive sign for South Korea’s stem cell space, one of the government’s priorities in the biotech sector, K-Stemcell will begin late-stage clinical trials with JOINTSTEM, an autologus adipose-derived stem cell therapy for degenerative arthritis, with a goal of commercialization in 2018.